ArticleBMC gastroenterology2022

Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.

Rogério Serafim Parra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.